

Jean-Paul Pirnay

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5680493/publications.pdf>

Version: 2024-02-01

107
papers

6,332
citations

61687

45
h-index

84171

75
g-index

111
all docs

111
docs citations

111
times ranked

5924
citing authors

#	ARTICLE	IF	CITATIONS
1	Recent progress toward the implementation of phage therapy in Western medicine. <i>FEMS Microbiology Reviews</i> , 2022, 46, .	3.9	50
2	European regulatory aspects of phage therapy: magistral phage preparations. <i>Current Opinion in Virology</i> , 2022, 52, 24-29.	2.6	32
3	Combination of pre-adapted bacteriophage therapy and antibiotics for treatment of fracture-related infection due to pandrug-resistant <i>Klebsiella pneumoniae</i> . <i>Nature Communications</i> , 2022, 13, 302.	5.8	97
4	Parallel evolution of <i>Pseudomonas aeruginosa</i> phage resistance and virulence loss in response to phage treatment in vivo and in vitro. <i>ELife</i> , 2022, 11, .	2.8	31
5	Screening of Anorectal and Oropharyngeal Samples Fails to Detect Bacteriophages Infecting <i>Neisseria gonorrhoeae</i> . <i>Antibiotics</i> , 2022, 11, 268.	1.5	1
6	Safety and efficacy of phage therapy in difficult-to-treat infections: a systematic review. <i>Lancet Infectious Diseases</i> , The, 2022, 22, e208-e220.	4.6	125
7	In Vitro and In Vivo Assessments of Two Newly Isolated Bacteriophages against an ST13 Urinary Tract Infection <i>Klebsiella pneumoniae</i> . <i>Viruses</i> , 2022, 14, 1079.	1.5	6
8	In Vitro Techniques and Measurements of Phage Characteristics That Are Important for Phage Therapy Success. <i>Viruses</i> , 2022, 14, 1490.	1.5	34
9	Bacteriophages: it's a medicine, Jim, but not as we know it. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 309-311.	4.6	32
10	A Case of Phage Therapy against Pandrug-Resistant <i>Achromobacter xylosoxidans</i> in a 12-Year-Old Lung-Transplanted Cystic Fibrosis Patient. <i>Viruses</i> , 2021, 13, 60.	1.5	65
11	Genomics of an endemic cystic fibrosis <i>Burkholderia multivorans</i> strain reveals low within-patient evolution but high between-patient diversity. <i>PLoS Pathogens</i> , 2021, 17, e1009418.	2.1	11
12	Evaluation of the Stability of Bacteriophages in Different Solutions Suitable for the Production of Magistral Preparations in Belgium. <i>Viruses</i> , 2021, 13, 865.	1.5	34
13	Variant Analysis of SARS-CoV-2 Genomes from Belgian Military Personnel Engaged in Overseas Missions and Operations. <i>Viruses</i> , 2021, 13, 1359.	1.5	6
14	Evaluating Diagnostic Accuracy of Saliva Sampling Methods for Severe Acute Respiratory Syndrome Coronavirus 2 Reveals Differential Sensitivity and Association with Viral Load. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 1249-1258.	1.2	7
15	Bacteriophage Therapy for Difficult-to-Treat Infections: The Implementation of a Multidisciplinary Phage Task Force (The PHAGEFORCE Study Protocol). <i>Viruses</i> , 2021, 13, 1543.	1.5	21
16	A Case of In Situ Phage Therapy against <i>Staphylococcus aureus</i> in a Bone Allograft Polymicrobial Biofilm Infection: Outcomes and Phage-Antibiotic Interactions. <i>Viruses</i> , 2021, 13, 1898.	1.5	18
17	A Design of Experiment Approach to Optimize Spray-Dried Powders Containing <i>Pseudomonas aeruginosa</i> Podoviridae and Myoviridae Bacteriophages. <i>Viruses</i> , 2021, 13, 1926.	1.5	7
18	Successful case of adjunctive intravenous bacteriophage therapy to treat left ventricular assist device infection. <i>Journal of Infection</i> , 2021, 83, e1-e3.	1.7	14

#	ARTICLE	IF	CITATIONS
19	Bacteriophage Rescue Therapy of a Vancomycin-Resistant <i>Enterococcus faecium</i> Infection in a One-Year-Old Child following a Third Liver Transplantation. <i>Viruses</i> , 2021, 13, 1785.	1.5	29
20	Epidemiology and etiology of blood stream infections in a Belgian burn wound center. <i>Acta Clinica Belgica</i> , 2021, , 1-7.	0.5	3
21	In Vitro Evaluation of the Therapeutic Potential of Phage VA7 against Enterotoxigenic <i>Bacteroides fragilis</i> Infection. <i>Viruses</i> , 2021, 13, 2044.	1.5	3
22	Phage Therapy. <i>WikiJournal of Medicine</i> , 2021, 8, 4.	1.0	1
23	Bacteriophage Therapy for the Prevention and Treatment of Fracture-Related Infection Caused by <i>Staphylococcus aureus</i> : a Preclinical Study. <i>Microbiology Spectrum</i> , 2021, 9, e0173621.	1.2	15
24	The Unique Role That WHO Could Play in Implementing Phage Therapy to Combat the Global Antibiotic Resistance Crisis. <i>Frontiers in Microbiology</i> , 2020, 11, 1982.	1.5	6
25	Study of a SARS-CoV-2 Outbreak in a Belgian Military Education and Training Center in Maradi, Niger. <i>Viruses</i> , 2020, 12, 949.	1.5	19
26	Characterization of <i>Salmonella</i> Isolates from Various Geographical Regions of the Caucasus and Their Susceptibility to Bacteriophages. <i>Viruses</i> , 2020, 12, 1418.	1.5	15
27	Phage Therapy in the Year 2035. <i>Frontiers in Microbiology</i> , 2020, 11, 1171.	1.5	58
28	Prevalence of <i>Anaplasma phagocytophilum</i> in humans in Belgium for the period 2013â€“2016.. <i>Acta Clinica Belgica</i> , 2019, 74, 280-285.	0.5	4
29	Development of a qPCR platform for quantification of the five bacteriophages within bacteriophage cocktail 2 (BFC2). <i>Scientific Reports</i> , 2019, 9, 13893.	1.6	19
30	Bacteriophage Application for Difficult-to-treat Musculoskeletal Infections: Development of a Standardized Multidisciplinary Treatment Protocol. <i>Viruses</i> , 2019, 11, 891.	1.5	98
31	Processing Phage Therapy Requests in a Brussels Military Hospital: Lessons Identified. <i>Viruses</i> , 2019, 11, 265.	1.5	62
32	Clinical application of bacteriophages in Europe. <i>Microbiology Australia</i> , 2019, 40, 8.	0.1	16
33	Production of Phage Therapeutics and Formulations: Innovative Approaches. , 2019, , 3-41.		2
34	Phage Therapy in Europe: Regulatory and Intellectual Property Protection Issues. , 2019, , 363-377.		2
35	Bacteriophage Production in Compliance with Regulatory Requirements. <i>Methods in Molecular Biology</i> , 2018, 1693, 233-252.	0.4	34
36	Guidelines to Compose an Ideal Bacteriophage Cocktail. <i>Methods in Molecular Biology</i> , 2018, 1693, 99-110.	0.4	78

#	ARTICLE	IF	CITATIONS
37	Biological tests carried out on serum/plasma samples from donors of human body material for transplantation: Belgian experience and practical recommendations. <i>Cell and Tissue Banking</i> , 2018, 19, 681-695.	0.5	4
38	Silk Route to the Acceptance and Re-Implementation of Bacteriophage Therapyâ€”Part II. <i>Antibiotics</i> , 2018, 7, 35.	1.5	46
39	The Magistral Phage. <i>Viruses</i> , 2018, 10, 64.	1.5	232
40	Selection of Potential Therapeutic Bacteriophages that Lyse a CTX-M-15 Extended Spectrum Î²-Lactamase Producing <i>Salmonella enterica</i> Serovar Typhi Strain from the Democratic Republic of the Congo. <i>Viruses</i> , 2018, 10, 172.	1.5	22
41	Pseudomonads from wild free-living sea turtles in PrÃƒncipe Island, Gulf of Guinea. <i>Ecological Indicators</i> , 2017, 81, 260-264.	2.6	4
42	Use of bacteriophages in the treatment of colistin-only-sensitive <i>Pseudomonas aeruginosa</i> septicemia in a patient with acute kidney injuryâ€”a case report. <i>Critical Care</i> , 2017, 21, 129.	2.5	185
43	Application of bacteriophages. <i>Microbiology Australia</i> , 2017, 38, 63.	0.1	18
44	Stability of bacteriophages in burn wound care products. <i>PLoS ONE</i> , 2017, 12, e0182121.	1.1	47
45	The Developing World Urgently Needs Phages to Combat Pathogenic Bacteria. <i>Frontiers in Microbiology</i> , 2016, 7, 882.	1.5	63
46	Molecular Epidemiology and Clinical Impact of <i>Acinetobacter calcoaceticus-baumannii</i> Complex in a Belgian Burn Wound Center. <i>PLoS ONE</i> , 2016, 11, e0156237.	1.1	39
47	Antimicrobial resistance and genomic rep-PCR fingerprints of <i>Pseudomonas aeruginosa</i> strains from animals on the background of the global population structure. <i>BMC Veterinary Research</i> , 2016, 13, 58.	0.7	14
48	Silk route to the acceptance and reâ€™plementation of bacteriophage therapy. <i>Biotechnology Journal</i> , 2016, 11, 595-600.	1.8	54
49	Preâ€™adapting parasitic phages to a pathogen leads to increased pathogen clearance and lowered resistance evolution with <i>Pseudomonas aeruginosa</i> cystic fibrosis bacterial isolates. <i>Journal of Evolutionary Biology</i> , 2016, 29, 188-198.	0.8	83
50	Bacteriophage therapy: Fast-forward to the past lessons identified from the advanced therapy regulation. <i>Burns</i> , 2016, 42, 11-12.	1.1	7
51	A bacteriophage journey at the European Medicines Agency. <i>FEMS Microbiology Letters</i> , 2016, 363, fnv225.	0.7	67
52	Access to bacteriophage therapy: discouraging experiences from the human cell and tissue legal framework. <i>FEMS Microbiology Letters</i> , 2016, 363, fnv241.	0.7	11
53	Increase of efflux-mediated resistance in <i>Pseudomonas aeruginosa</i> during antibiotic treatment in patients suffering from nosocomial pneumonia. <i>International Journal of Antimicrobial Agents</i> , 2016, 47, 77-83.	1.1	20
54	Access to human tissues for research and product development. <i>EMBO Reports</i> , 2015, 16, 557-562.	2.0	28

#	ARTICLE	IF	CITATIONS
55	Clinical utilization of genomics data produced by the international <i>Pseudomonas aeruginosa</i> consortium. <i>Frontiers in Microbiology</i> , 2015, 6, 1036.	1.5	144
56	Recellularizing of human acellular dermal matrices imaged by high-definition optical coherence tomography. <i>Experimental Dermatology</i> , 2015, 24, 349-354.	1.4	4
57	The Widespread Multidrug-Resistant Serotype O12 <i>Pseudomonas aeruginosa</i> Clone Emerged through Concomitant Horizontal Transfer of Serotype Antigen and Antibiotic Resistance Gene Clusters. <i>MBio</i> , 2015, 6, e01396-15.	1.8	47
58	Quality and Safety Requirements for Sustainable Phage Therapy Products. <i>Pharmaceutical Research</i> , 2015, 32, 2173-2179.	1.7	176
59	Correlation between cytotoxicity induced by <i>Pseudomonas aeruginosa</i> clinical isolates from acute infections and IL-1 β secretion in a model of human THP-1 monocytes. <i>Pathogens and Disease</i> , 2015, 73, ftv049.	0.8	16
60	In the Name of Quality and Safety: Commercialization of Human Cells and Tissues. , 2015, , 265-284.		0
61	O serotype-independent susceptibility of <i>Pseudomonas aeruginosa</i> to lectin-like pyocins. <i>MicrobiologyOpen</i> , 2014, 3, 875-884.	1.2	18
62	Real-time three-dimensional imaging of epidermal splitting and removal by high-definition optical coherence tomography. <i>Experimental Dermatology</i> , 2014, 23, 725-730.	1.4	9
63	Taking Bacteriophage Therapy Seriously: A Moral Argument. <i>BioMed Research International</i> , 2014, 2014, 1-8.	0.9	31
64	Effectiveness of bacteriophages in the sputum of cystic fibrosis patients. <i>Clinical Microbiology and Infection</i> , 2014, 20, O983-O990.	2.8	58
65	Characterization of Newly Isolated Lytic Bacteriophages Active against <i>Acinetobacter baumannii</i> . <i>PLoS ONE</i> , 2014, 9, e104853.	1.1	80
66	Call for a Dedicated European Legal Framework for Bacteriophage Therapy. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2014, 62, 117-129.	1.0	71
67	Art-175 Is a Highly Efficient Antibacterial against Multidrug-Resistant Strains and Persists of <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3774-3784.	1.4	152
68	Engineered Endolysin-Based "Artilylins" To Combat Multidrug-Resistant Gram-Negative Pathogens. <i>MBio</i> , 2014, 5, e01379-14.	1.8	279
69	Experimental phage therapy of burn wound infection: difficult first steps. <i>International Journal of Burns and Trauma</i> , 2014, 4, 66-73.	0.2	111
70	Cleanrooms and tissue banking how happy I could be with either GMP or GTP?. <i>Cell and Tissue Banking</i> , 2013, 14, 571-578.	0.5	5
71	Evaluation of <i>oprI</i> and <i>oprL</i> genes as molecular markers for the genus <i>Pseudomonas</i> and their use in studying the biodiversity of a small Belgian River. <i>Research in Microbiology</i> , 2013, 164, 254-261.	1.0	30
72	Developing an international <i>Pseudomonas aeruginosa</i> reference panel. <i>MicrobiologyOpen</i> , 2013, 2, 1010-1023.	1.2	94

#	ARTICLE	IF	CITATIONS
73	Business oriented EU human cell and tissue product legislation will adversely impact Member States' health care systems. <i>Cell and Tissue Banking</i> , 2013, 14, 525-560.	0.5	46
74	Paving a regulatory pathway for phage therapy. <i>EMBO Reports</i> , 2013, 14, 951-954.	2.0	32
75	Stability of <i>Staphylococcus aureus</i> Phage ISP after Freeze-Drying (Lyophilization). <i>PLoS ONE</i> , 2013, 8, e68797.	1.1	99
76	Effects of Sequential and Simultaneous Applications of Bacteriophages on Populations of <i>Pseudomonas aeruginosa</i> <i>In Vitro</i> and in Wax Moth Larvae. <i>Applied and Environmental Microbiology</i> , 2012, 78, 5646-5652.	1.4	139
77	Introducing yesterday's phage therapy in today's medicine. <i>Future Virology</i> , 2012, 7, 379-390.	0.9	80
78	Beware of the commercialization of human cells and tissues: situation in the European Union. <i>Cell and Tissue Banking</i> , 2012, 13, 487-498.	0.5	11
79	Optimizing the European Regulatory Framework for Sustainable Bacteriophage Therapy in Human Medicine. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2012, 60, 161-172.	1.0	67
80	Evaluation of a microbiological screening and acceptance procedure for cryopreserved skin allografts based on 14-day cultures. <i>Cell and Tissue Banking</i> , 2012, 13, 287-295.	0.5	24
81	Glycerol treatment as recovery procedure for cryopreserved human skin allografts positive for bacteria and fungi. <i>Cell and Tissue Banking</i> , 2012, 13, 1-7.	0.5	17
82	Feeder layer- and animal product-free culture of neonatal foreskin keratinocytes: improved performance, usability, quality and safety. <i>Cell and Tissue Banking</i> , 2012, 13, 175-189.	0.5	45
83	Selection and Characterization of a Candidate Therapeutic Bacteriophage That Lyses the <i>Escherichia coli</i> O104:H4 Strain from the 2011 Outbreak in Germany. <i>PLoS ONE</i> , 2012, 7, e52709.	1.1	48
84	Actin dynamics regulate immediate PAR-2-dependent responses to acute epidermal permeability barrier abrogation. <i>Journal of Dermatological Science</i> , 2011, 61, 101-109.	1.0	12
85	Schistosomiasis in Belgian Military Personnel Returning From the Democratic Republic of Congo. <i>Military Medicine</i> , 2011, 176, 1341-1346.	0.4	18
86	Microbiological and Molecular Assessment of Bacteriophage ISP for the Control of <i>Staphylococcus aureus</i> . <i>PLoS ONE</i> , 2011, 6, e24418.	1.1	92
87	Potential release of aluminum and other metals by food-grade aluminum foil used for skin allograft cryo preservation. <i>Cell and Tissue Banking</i> , 2011, 12, 241-246.	0.5	2
88	The Phage Therapy Paradigm: Præ-Porter or Sur-mesure?. <i>Pharmaceutical Research</i> , 2011, 28, 934-937.	1.7	249
89	Human cells and tissues: the need for a global ethical framework. <i>Bulletin of the World Health Organization</i> , 2010, 88, 870-872.	1.5	15
90	In vivo development of antimicrobial resistance in <i>Pseudomonas aeruginosa</i> strains isolated from the lower respiratory tract of Intensive Care Unit patients with nosocomial pneumonia and receiving antipseudomonal therapy. <i>International Journal of Antimicrobial Agents</i> , 2010, 36, 513-522.	1.1	72

#	ARTICLE	IF	CITATIONS
91	<i>Pseudomonas aeruginosa</i> Population Structure Revisited. PLoS ONE, 2009, 4, e7740.	1.1	223
92	Comparison of the sensitivity of culture, PCR and quantitative real-time PCR for the detection of <i>Pseudomonas aeruginosa</i> in sputum of cystic fibrosis patients. BMC Microbiology, 2009, 9, 244.	1.3	56
93	Survey of <i>Pseudomonas aeruginosa</i> and its phages: <i>de novo</i> peptide sequencing as a novel tool to assess the diversity of worldwide collected viruses. Environmental Microbiology, 2009, 11, 1303-1313.	1.8	32
94	Distribution and evolution of ferripyoverdine receptors in <i>Pseudomonas aeruginosa</i> . Environmental Microbiology, 2009, 11, 2123-2135.	1.8	54
95	Quality-Controlled Small-Scale Production of a Well-Defined Bacteriophage Cocktail for Use in Human Clinical Trials. PLoS ONE, 2009, 4, e4944.	1.1	391
96	European regulatory conundrum of phage therapy. Future Microbiology, 2007, 2, 485-491.	1.0	81
97	Global <i>Pseudomonas aeruginosa</i> biodiversity as reflected in a Belgian river. Environmental Microbiology, 2005, 7, 969-980.	1.8	149
98	FpvB, an alternative type I ferripyoverdine receptor of <i>Pseudomonas aeruginosa</i> . Microbiology (United Kingdom), 2007, 164, 164-171.	0.7	164
99	Seoul hantavirus in Europe: first demonstration of the virus genome in wild <i>Rattus norvegicus</i> captured in France. European Journal of Clinical Microbiology and Infectious Diseases, 2004, 23, 711-7.	1.3	64
100	No easy way to exterminate "superbugs" at the dawn of the third millennium. Expert Review of Anti-Infective Therapy, 2003, 1, 523-525.	2.0	2
101	Molecular Epidemiology of <i>Pseudomonas aeruginosa</i> Colonization in a Burn Unit: Persistence of a Multidrug-Resistant Clone and a Silver Sulfadiazine-Resistant Clone. Journal of Clinical Microbiology, 2003, 41, 1192-1202.	1.8	151
102	Identification of new, conserved, non-ribosomal peptide synthetases from fluorescent pseudomonads involved in the biosynthesis of the siderophore pyoverdine. Molecular Microbiology, 2002, 45, 1673-1685.	1.2	118
103	Analysis of the <i>Pseudomonas aeruginosa</i> oprD gene from clinical and environmental isolates. Environmental Microbiology, 2002, 4, 872-882.	1.8	122
104	<i>Pseudomonas aeruginosa</i> displays an epidemic population structure. Environmental Microbiology, 2002, 4, 898-911.	1.8	106
105	Quantitation of <i>Pseudomonas aeruginosa</i> in wound biopsy samples: from bacterial culture to rapid "real-time" polymerase chain reaction. Critical Care, 2000, 4, 255-61.	2.5	48
106	Analysis of epidemic <i>Pseudomonas aeruginosa</i> isolated by isoelectric focusing of pyoverdine and RAPD-PCR: modern tools for an integrated anti-nosocomial infection strategy in burn wound centres. Burns, 1997, 23, 379-386.	1.1	34
107	HIV transmission by transplantation of allograft skin: a review of the literature. Burns, 1997, 23, 1-5.	1.1	25